8-K: Cibus Announces Strategic Realignment and Third Quarter 2024 Financial Results

Cibus reports third quarter financial results, announces a strategic realignment to focus on key commercial opportunities, and details progress in its gene editing technology.

Summary

• Cibus announced its third quarter 2024 financial results and provided a business update, highlighting a strategic realignment to focus on commercial opportunities.
• The company is prioritizing its weed management platform for rice, pod shatter reduction in canola, sclerotinia resistance for canola and soybean, and soybean platform development.
• Cibus has made significant progress in rice, with agreements with four major seed companies and successful field trials of its HT3 trait.
• They have also completed initial field trials for pod shatter reduction in canola in the UK and are progressing with sclerotinia resistance.
• The soybean platform is expected to be operational by the end of 2024.
• Cibus is implementing cost-saving measures expected to achieve $10 million in annualized savings and reduce monthly cash usage by approximately 20%.
• The company reported a net loss of $201.5 million for the quarter, primarily due to a $181.4 million non-cash goodwill impairment.
• Cash and cash equivalents were $28.8 million as of September 30, 2024, expected to fund operations into late in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in technology and commercialization, the significant net loss and limited cash runway temper the overall sentiment. The strategic realignment and cost-saving measures are positive steps, but the need for additional funding is a concern.

Positives

• Cibus has made significant progress in its rice platform, securing agreements with four major seed companies and completing successful field trials.
• The company's pod shatter reduction trials in the UK have been successful, marking an important step in commercialization.
• The soybean platform is on track to be operational by the end of 2024, opening access to a large market.
• Cost-saving initiatives are expected to reduce monthly cash usage by approximately 20%.
• Cibus has expanded its IP portfolio with additional patents across 10 plant gene editing and trait families.
• Canada has added to the growing list of countries regulating Cibus' gene editing technologies similar to conventional breeding.

Negatives

• Cibus reported a significant net loss of $201.5 million for the quarter, primarily due to a $181.4 million non-cash goodwill impairment.
• The company's cash and cash equivalents are expected to fund operations only into late in the first quarter of 2025.
• Year-over-year financial comparisons are not directly comparable due to the merger with Cibus Global, LLC in 2023.
• The company is incurring a one-time charge associated with severance expenses in the fourth quarter of fiscal 2024.

Risks

• Cibus needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital on acceptable terms.
• There are risks associated with competition, intellectual property protection, and the time and resources required for product development.
• The company relies on third parties for development activities and faces challenges in licensing its traits.
• There is a risk that farmers may not recognize the value in germplasm containing Cibus' traits.
• Regulatory developments could disfavor or impose burdens on gene-editing processes or products.
• The company faces risks related to commodity prices and other market conditions in the agricultural sector.
• There are risks associated with the company's ability to achieve commercial success.

Future Outlook

Cibus expects its existing cash and cash equivalents to fund planned operating expenses and capital expenditure requirements into late in the first quarter of 2025. The company intends to report ordinary course development progress and achievements in connection with its quarterly reporting process. Cibus is focused on achieving key milestones for its priority programs in the remainder of 2024 and 2025, including the operational launch of its soybean platform, sclerotinia resistance testing, and HT2 field trials.

Management Comments

• Rory Riggs, Co-Founder, Chairman, and CEO of Cibus, stated that all operational crop platforms now have field studies or greenhouse data with multiple traits and customer relationships.
• Mr. Riggs mentioned that the company is actively working with customers to advance germplasm with their traits toward commercialization.
• Mr. Riggs highlighted the strategic realignment to focus capital resources on commercial efforts.
• Mr. Riggs noted that the Rice platform exemplifies the progress made with HT1 and HT3 herbicide traits.
• Mr. Riggs stated that the company is setting the stage for a new industry of gene-edited traits.

Industry Context

This announcement reflects the growing trend in agricultural biotechnology towards gene editing for crop improvement. Cibus is positioning itself as a leader in this space, focusing on traits that address critical challenges such as disease resistance and herbicide tolerance. The company's partnerships with major seed companies and its focus on commercialization are aligned with industry trends towards integrating gene editing technologies into mainstream agriculture.

Comparison to Industry Standards

• Cibus's Trait Machine process, which allows for rapid editing of a customer's elite germplasm, is a significant advancement compared to traditional breeding methods, which can take many years.
• The company's focus on multiple crops, including rice, canola, and soybean, aligns with the industry's need for diverse solutions to agricultural challenges.
• While companies like Corteva and Bayer also invest in gene editing, Cibus's approach of licensing traits to seed companies is a different business model.
• The reported net loss and cash position highlight the challenges faced by many biotech companies in the early stages of commercialization, which is common in the industry.
• The cost-saving measures and strategic realignment are similar to actions taken by other biotech companies to manage resources and focus on key priorities.

Related Party Transactions

• Royalty liability interest expense related parties was $8.9 million for the quarter ended September 30, 2024, compared to $8.1 million in the year-ago period.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the need for additional funding.
• Employees are affected by the cost-saving initiatives, including potential severance expenses.
• Customers, particularly seed companies, are impacted by the progress in trait development and commercialization.
• Suppliers and creditors are impacted by the company's financial performance and cash position.

Next Steps

• Cibus expects its Soybean platform to be operational by the end of 2024.
• The company plans to continue greenhouse testing for Sclerotinia resistance in Canola, with field trials planned for 2025.
• Cibus anticipates initial field trial data for HT2 in Canola in 2025.
• The company will continue progress on its partner-funded sustainable ingredient development project.
• Cibus intends to report ordinary course development progress and achievements in connection with its quarterly reporting process.

Key Dates

Keywords

gene editing, agricultural biotechnology, plant traits, weed management, herbicide tolerance, sclerotinia resistance, pod shatter reduction, soybean platform, rice, canola, cost savings, commercialization, trait machine, intellectual property